Objective To investigate the efficacy and safety of elemene injection combined with gemcitabine+cispla-tin(first-line chemotherapy regimen)in the treatment of non-small cell lung cancer(NSCLC).Method A total of 78 pa-tients with NSCLC were divided into observation group and control group according to different treatment methods,with 39 cases in each group.The control group received gemcitabine+cisplatin treatment,and the observation group received elemene injection treatment on the basis of the control group.The clinical efficacy,immune function indicators[CD3+,natural killer(NK)cell,CD4+/CD8+],quality of life[Karnofsky performance status(KPS)score]and the incidence of ad-verse reactions were compared between the two groups.Result The total effective rate of observation group was higher than that of control group,and the difference was statistically significant(P＜0.05).After treatment,the CD3+,NK cells and CD4+/CD8+in two groups were lower than those before treatment,the KPS scores were higher than those before treat-ment,the CD3+,NK cell,CD4+/CD8+ and KPS score in observation group were higher than those in control group,and the differences were statistically significant(P＜0.05).There were no significant differences in the incidence of adverse re-actions between the two groups(P＞0.05).Conclusion Elemene injection combined with gemcitabine+cisplatin in the treatment of NSCLC patients can improve the therapeutic effect,immune function and quality of life,without increasing adverse reactions.
维普
万方数据